| 摘要 |
<p>The invention relates to the use of the human 'MAP kinase interacting kinases' Mnk2a or Mnk2b in methods for identification of pharmaceutically useful agents, in particular agents useful for the treatment of type II diabetes. The invention also relates to methods of treating or preventing medical conditions relating to insulin resistance by modulating the expression or activity of Mnk2a or Mnk2b.</p> |
